| Title |
Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy
|
|---|---|
| Published in |
Drug Design, Development and Therapy, May 2012
|
| DOI | 10.2147/dddt.s30908 |
| Pubmed ID | |
| Authors |
Franco Frati, Cristoforo Incorvaia, Marie David, Silvia Scurati, Simona Seta, Guglielmo Padua, Eleonora Cattaneo, Carlo Cavaliere, Alessia Di Rienzo, Ilaria Dell’Albani, Paola Puccinelli |
| Abstract |
The house dust mite is a major cause of respiratory allergy worldwide. The management of mite allergy is based on avoidance measures, drug treatment, and allergen immunotherapy, but only allergen immunotherapy is able to modify the natural history of the disease. Injectable subcutaneous immunotherapy was introduced a century ago, while sublingual immunotherapy was proposed in the 1980s and emerged in the ensuing years as an effective and safe option to subcutaneous immunotherapy. However, the quality of the extracts to be used in allergen immunotherapy is crucial for the success of treatment. The mite extract for sublingual immunotherapy known as Staloral 300 was developed to offer optimal characteristics concerning the mite culture medium, standardization, and allergen dose. Double-blind, placebo-controlled trials with Staloral 300 have provided a substantial part of the clinical evidence analyzed in a meta-analysis of the efficacy of allergen immunotherapy in mite-induced rhinitis and asthma. Safety and tolerability are very good, mild local reactions in the mouth being the most common side effect. This makes it feasible to carry out sublingual immunotherapy for the 3-5-year duration needed to achieve long-lasting tolerance to the specific allergen. The performance of Staloral 300 may provide optimal conditions for an effective and safe sublingual immunotherapy in patients with mite-induced respiratory allergy. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| India | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 67% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Austria | 1 | 2% |
| Unknown | 45 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 22% |
| Other | 6 | 13% |
| Student > Master | 4 | 9% |
| Student > Bachelor | 3 | 7% |
| Student > Ph. D. Student | 3 | 7% |
| Other | 10 | 22% |
| Unknown | 10 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 37% |
| Agricultural and Biological Sciences | 7 | 15% |
| Biochemistry, Genetics and Molecular Biology | 5 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Immunology and Microbiology | 2 | 4% |
| Other | 3 | 7% |
| Unknown | 10 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 March 2013.
All research outputs
#15,048,620
of 25,584,565 outputs
Outputs from Drug Design, Development and Therapy
#799
of 2,254 outputs
Outputs of similar age
#100,840
of 176,069 outputs
Outputs of similar age from Drug Design, Development and Therapy
#3
of 5 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,254 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 176,069 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.